Zypadhera

Selected form

Olanzapine

Method of action: Antipsychotic, Psychoanaleptics, Psycholeptics

Treatment option: Delirium, Hallucinations, Schizophrenia

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zypadhera

Quick Facts: Zypadhera

Property	Description
Active ingredient	Olanzapine (as the pamoate monohydrate salt)
Form	Powder and solvent for prolonged-release suspension
Pharmacological class	Atypical Antipsychotic (Second-Generation)
Primary Mechanism	Selective antagonism of dopamine and serotonin receptors
Origin	Synthetic, thienobenzodiazepine derivative

1. Defining Zypadhera: An Atypical Antipsychotic Medicine

Zypadhera is the trade name for the prescription medicine Olanzapine long-acting injection (OLAI), which is classified as an atypical antipsychotic, or second-generation psychotropic agent. Its core active ingredient is Olanzapine, a synthetic compound derived from the thienobenzodiazepine chemical class. Olanzapine acts as a selective monoaminergic antagonist by modulating the activity of crucial chemical messengers in the brain. This regulatory action is necessary for stabilizing thought and emotional processes. This class of medication is used for maintaining patient stability during continuation therapy.

2. Composition and Prolonged-Release Form

The medication is supplied as a sterile powder and solvent that must be mixed to form a prolonged-release suspension for injection. The active drug is formulated as Olanzapine pamoate monohydrate, a specific salt form of olanzapine with very low solubility, which is the compositional factor enabling its extended action. This composition is fundamentally different from oral tablets, as it is engineered for deep intramuscular gluteal injection. The prolonged-release characteristic arises from the slow dissolution of the pamoate salt in the muscle tissue, allowing the active compound to be absorbed gradually and steadily into the bloodstream over several weeks.

3. General Therapeutic Goal of the Long-Acting Injection

The primary therapeutic goal of this long-acting injectable (LAI) form is to support continuous, sustained management for conditions requiring stable chemical balancing within the central nervous system. The prolonged delivery mechanism is designed to provide therapeutic drug levels over an extended period, which is a major advantage compared to the daily requirement of oral medication. By achieving this consistent, continuous release, the medication aids in the long-term stabilization of emotional and cognitive function, which is critical for supporting treatment adherence in chronic care management.

What side effects are possible with Zypadhera?

Possible Side Effects and Safety Information

The safety profile for Zypadhera (olanzapine long-acting injection) is structured by the official classification of potential adverse reactions and specific usage restrictions defined in government regulatory documents.

Adverse Reaction Categories

Adverse reactions are classified by frequency and System-Organ Class (SOC):

Classification	Examples of Effects
Very Common (ge 1 in 10)	Weight increase, Somnolence, Orthostatic hypotension
Common (1 in 100 to < 1 in 10)	Neutropenia, Headache, Injection site pain, Hyperglycemia
Uncommon (1 in 1,000 to < 1 in 100)	Seizures, Bradycardia, Post-Injection Delirium/Sedation Syndrome (PDSS)

Major categories affected include Metabolism and Nutrition Disorders (e.g., weight gain, dyslipidemia) and Nervous System Disorders (e.g., sedation, dizziness, extrapyramidal symptoms).

Serious Adverse Reactions and Restrictions

Post-Injection Delirium/Sedation Syndrome (PDSS) is a unique and serious adverse reaction associated with this injectable formulation, typically appearing within one hour post-injection, and necessitates a mandatory three-hour patient observation period after each administration as defined in regulatory labels.

Other serious risks include Neuroleptic Malignant Syndrome (NMS) and severe metabolic complications such as Hyperglycemia that may lead to ketoacidosis. The risk of Tardive Dyskinesia is noted to increase with the duration of treatment.

Official restrictions prohibit the use of this medicine in elderly patients with dementia-related psychosis due to an increased risk of death and Cerebrovascular Adverse Events (CVAE). The medicine is also contraindicated in individuals with known olanzapine hypersensitivity or certain forms of narrow-angle glaucoma.

Overdose and Emergency Response

Overdose and When to Seek Help

Zypadhera (olanzapine prolonged-release injectable suspension) carries a specific risk of Post-injection syndrome (PIS), a rare but serious reaction with signs and symptoms consistent with olanzapine overdose.

Documented Overdose Symptoms

The symptoms associated with PIS and overdose are primarily neurological and can include sedation (ranging from mild to coma) and/or delirium, which involves confusion, disorientation, agitation, anxiety, or other forms of cognitive impairment. Other potential acute signs can include an unusually fast heartbeat, problems with speech, and unusual movements of the face or tongue.

Required Emergency Actions

Due to the risk of PIS, every patient must be observed in a healthcare facility for at least three hours after each injection. During this period, healthcare personnel must confirm that the patient is alert, oriented, and free of any signs of overdose before discharge. This observation period may be extended if any symptoms consistent with overdose are noted.

Immediate medical help is required if a patient develops any symptoms of overdose, particularly if they occur more than three hours after the injection. Patients must be advised to be vigilant and seek assistance right away if these signs appear after leaving the clinic.

Therapeutic Uses of Zypadhera

Zypadhera is commonly used for the long-term maintenance treatment of adult patients with schizophrenia who may already be stabilized on oral olanzapine.

Managing Symptoms and Preventing Schizophrenia Relapse

This medication is applied in addressing the positive psychotic symptoms characteristic of schizophrenia, which may include disruptive manifestations like hallucinations and delusions. Its primary role is to support the stability achieved during initial treatment and help manage the return of these symptoms. By providing consistent therapeutic levels, the medication offers supportive relief that helps ease the overall symptom burden.

Supporting Consistent Medication Adherence

A major benefit is its use in scenarios where functional stability becomes affected by the challenge of consistent, reliable intake of daily oral medication. The prolonged-release nature of the injection is designed to provide continuous, predictable medication levels over several weeks. This continuous coverage assists with maintaining a sense of stability when symptoms are more noticeable, which may support general well-being during symptomatic phases.

Quick Fact: Management of Positive Psychotic Symptoms

The primary therapeutic purpose is the maintenance management of symptoms, including disturbances in thought organization, suspiciousness, and misperceptions.

Eligibility and Restrictions for Use

The eligibility for Zypadhera (olanzapine prolonged-release injection) is strictly defined by regulatory guidelines, focusing on specific population groups and clinical conditions.

Contraindicated Populations

Category	Regulatory Statement
Absolute Contraindications	Contraindicated in patients with known hypersensitivity to olanzapine or its components, or those with known risk of narrow-angle glaucoma [Source 1.1, 1.4].
High-Risk Exclusion	Not approved for use in elderly patients with dementia-related psychosis due to an increased risk of death and cerebrovascular events [Source 1.3].

Age and Condition-Based Restrictions

Category	Regulatory Statement
Approved Age Group	Adult patients (18 years and older) who are stabilized on oral olanzapine [Source 1.4].
Pediatric Use	Not recommended for children and adolescents under 18 years; safety and efficacy have not been established [Source 1.4].
Geriatric Use	Not recommended for patients over 65 years, and not recommended to be started in those over 75 years, unless a stable oral olanzapine dose has been verified [Source 1.4].
Organ Impairment	Use should not be used in patients with renal or hepatic impairment unless a well-tolerated and effective dose of oral olanzapine is established [Source 1.4].
Pregnancy/Lactation	Pregnancy: Use only if the potential benefit justifies the potential risk to the fetus. Lactation: Breast-feeding is not recommended [Source 2.4].

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Zypadhera (olanzapine extended-release injectable suspension) based on its metabolism and central nervous system effects.

Key Interaction Categories

The most significant documented interactions are categorized by their mechanism and resulting clinical recommendation:

Interaction Domain	Mechanism or Resulting Effect	Constraint/Recommendation
CYP1A2 Inhibitors	Inhibition of olanzapine metabolism	Lower starting or decreased olanzapine dose may be considered (e.g., fluvoxamine, ciprofloxacin)
CYP1A2 Inducers	Increased olanzapine clearance/reduced concentration	Clinical monitoring recommended; dose increase may be considered (e.g., carbamazepine, smoking)
Centrally Acting Drugs and Alcohol	Additive central nervous system (CNS) depressant effects and potential for increased hypotension	Use caution (e.g., diazepam, alcohol)
Antihypertensive Agents	Potential to enhance blood pressure lowering effect	Use caution
QTc-Prolonging Medicines	Potential for increased cardiac effects	Use caution

Specific Restrictions and Constraints

Olanzapine may antagonize the effects of dopamine agonists. The co-administration with anti-Parkinsonian medicinal products is not recommended in patients with Parkinson's disease and dementia. Due to the potential for severe adverse reactions, caution should be exercised when co-administering with other CNS-acting agents or any product known to induce hypotension or sedation. These official constraints are based on the need to manage pharmacokinetic changes and additive pharmacological effects.

Mechanism of Action

How Zypadhera Works

Zypadhera's mechanism of action is rooted in the regulation of neurotransmitter signaling within the central nervous system (CNS). The drug is primarily defined by its antagonism (blocking) of key monoamine receptors, which influences physiological processes through its receptor binding profile.

Modulating Dopamine and Serotonin Signaling

The core activity involves the antagonism of the Dopamine D2 and Serotonin 5-HT2A receptors. D2 blockade reduces dopaminergic signal transmission in specific pathways. Concurrently, 5-HT2A blockade influences dopamine release in specific brain areas, utilizing dual receptor binding to adjust neurotransmitter dynamics within the CNS.

Influence on Metabolic and Autonomic Pathways

The drug engages secondary mechanisms by blocking Histamine H1 and Alpha-1 (alpha1) Adrenergic receptors. This broader receptor binding contributes to physiological adjustments in systems governing appetite, sleep-wake cycles, and blood pressure regulation, which are inherent consequences of the drug's overall pharmacological mechanism.

Dosage and Administration Information

Zypadhera (olanzapine pamoate extended-release injectable suspension, marketed as Zyprexa Relprevv in the US) is a long-acting intramuscular injection used for the maintenance treatment of schizophrenia in adult patients who have been sufficiently stabilised on oral olanzapine.

Administration and Monitoring

Method of Administration: Zypadhera must be administered only by a healthcare professional trained in the correct injection technique. It is given by deep intramuscular gluteal injection (into the buttock muscle). The drug must not be injected into a vein (intravenously) or under the skin (subcutaneously).
Dosing Schedule: The injection is typically given every two weeks or every four weeks. The specific dose (150 mg, 210 mg, 300 mg, or 405 mg) and interval are determined by your doctor, based on your previous oral olanzapine dose and individual clinical needs.

Post-Injection Observation

Mandatory Monitoring: Due to the risk of a serious adverse event known as Post-Injection Delirium/Sedation Syndrome (PDSS), you must be continuously observed by qualified healthcare staff at a registered facility for at least three hours after every injection. PDSS symptoms include excessive sleepiness, dizziness, confusion, disorientation, difficulty talking or walking, and high blood pressure.
Safety Precautions: For the remainder of the day after each injection, you should not drive, operate machinery, or engage in any activity that requires full alertness, even if you feel well upon leaving the healthcare facility. You should ensure that you can obtain assistance if needed.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zypadhera (Olanzapine LAI)

Evidence for Use in Schizophrenia Maintenance Treatment

Research for Zypadhera was conducted to explore its profile for the continuous management of schizophrenia symptoms in adults who are already clinically stable. Studies used for regulatory review were primarily Randomized Controlled Trials (RCTs). These short-to-intermediate-term studies explored outcomes related to how symptoms change over time, specifically measuring whether the long-acting injection was associated with reduced rates of periods of heightened symptom activity. Outcomes measured included the time taken for a patient to experience a psychotic relapse or exacerbation, as well as changes in scores on standardized symptom measurement scales.

Studies reported measurements of relapse prevention and symptom stability in the trials involving stabilized adults. Research monitored how symptoms evolved in the observed populations during the study period, which spanned approximately six months. Evidence contributes to the broader understanding of symptom patterns in patients receiving this formulation.

Comparative Evidence: Long-Acting Injection vs. Oral Olanzapine

A core component of the research involved comparative trials where the long-acting injection was studied against the standard daily oral form of olanzapine. These trials were designed to explore whether the long-acting injection was not less effective than the oral tablet in maintaining stability. Research examined outcomes describing episodic or acute changes. The primary trials explored whether the long-acting injection was non-inferior to the oral form in terms of outcomes reflecting episodic or acute changes. However, because the design focused on non-inferiority, the research does not establish a superior preventative effect compared to consistent daily use of the oral tablet.

What is Still Uncertain About the Research

Several aspects of the evidence landscape are noted as uncertain or limited in the scientific literature. Firstly, comparative evidence is lacking, as the research has not established direct, large-scale comparisons between Zypadhera and other available long-acting injectable antipsychotic medicines. Secondly, the follow-up durations were limited in the most rigorous controlled trials, meaning long-term effects are not fully established by high-certainty evidence. Finally, the existing evidence for the long-acting injection provides context but not individual predictions regarding whether an individual will respond similarly to the group patterns observed in the trials.

How should Zypadhera be stored and disposed of?

Storage and Disposal Requirements

Official regulatory information dictates specific conditions for storing and disposing of Zypadhera (olanzapine pamoate) to maintain its integrity and ensure safe handling.

Item	Regulatory Requirement
Unopened Vials Storage	Store the powder and solvent in the original packaging at controlled room temperature, 20 to 25 C (68 to 77 F), and protect from light [FDA Label; EMA SmPC].
Post-Reconstitution Stability	The suspension must be used immediately after reconstitution. If not used at once, the stability limit is 24 hours at 20 -25 C [EMA SmPC].
Child Safety	The medicine must be kept out of the sight and reach of children [EMA SmPC].
Disposal Instructions	Any unused portion of the reconstituted product must be discarded. Disposal of all unused medicine and waste materials must be carried out in accordance with local requirements [FDA Label; EMA SmPC].